A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the safety and acceptability of an intermittent and daily PrEP regimen using Tenofovir Disoproxil Fumarate plus Emtricitabine (FTC/TDF) in men and women at risk for HIV, and it will directly compare adherence and intracellular drug levels in daily and intermittent PrEP recipients. It will also evaluate the relationship between drug adherence, sexual behavior and intracellular drug levels with an intermittent PrEP regimen. In addition it will evaluate the relationship between adherence to an intermittent PrEP regimen and timing of sexual activity in relation to PrEP dosing. The study will use objective medication event monitoring medication event monitors (MEMS) adherence measurement and evaluate the feasibility of newer adherence measurements such as hair sampling and plasma drug levels. The study will also evaluate the feasibility of using SMS (text messages) to collect sexual activity data in an African setting. It will allow study teams and communities to prepare for potential subsequent larger trials of intermittent PrEP. This study is not sized to evaluate efficacy. If the intermittent PrEP regimen is shown to be safe, feasible in terms of adherence, and achieves intracellular drug levels similar to daily PrEP, these data could be used to design a larger phase 2 study with one or more intermittent PrEP regimens. The goal of such a trial would be to provide bridging data if daily PrEP regimens are found to be effective or to prepare for efficacy or non-inferiority trials of intermittent versus daily PrEP.

Investigation of immune responses associated with FTC/TDF will also be evaluated in the pilot study. The proportion of volunteers on FTC/TDF with HIV-specific immune responses, due to exposures that did not lead to established HIV infection, will be assessed at 2-3 time points and compared to responses in volunteers assigned to placebo. Immune responses may be correlated with risk behavior and host factors, such as human leukocyte antigen (HLA) type. As noted above, very few HIV infections are expected to occur during the study, so correlation of HIV-specific immune responses and protection from infection or attenuation of disease progression will not be possible until a larger study is conducted.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Women TDF-FTC Benchmark Study

NCT05057858

HIV Infections

ACTIVE_NOT_RECRUITING PHASE2

The Women TAF-FTC Benchmark Study

NCT05140954

HIV Infections

COMPLETED PHASE2/PHASE3

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795

HIV-1 Infection

COMPLETED PHASE3

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

NCT00122512

HIV Infections

TERMINATED PHASE2

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

NCT00122486

HIV Infections

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FTC/TDF- Daily

FTC/TDF dosed daily

Group Type EXPERIMENTAL

FTC/TDF

Intervention Type DRUG

emtricitabine/tenofovir disoproxil fumarate

FTC/TDF-Intermittent

FTC/TDF dosed intermittently

Group Type EXPERIMENTAL

FTC/TDF

Intervention Type DRUG

emtricitabine/tenofovir disoproxil fumarate

Placebo-Daily

Placebo dosed daily

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

Placebo-Intermittent

Placebo dosed intermittently

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FTC/TDF

emtricitabine/tenofovir disoproxil fumarate

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study
* Has understood the information provided and has provided written informed consent before any study-related procedures are performed
* Willing to undergo HIV testing, STI screening, HIV counselling and receive HIV and STI test results
* At risk for HIV infection as defined by at least one of the following:

* Current sexually-transmitted infection (STI) or STI in the previous 3 months
* In the past 3 months had multiple episodes of unprotected vaginal sex
* In the past 3 months had multiple episodes of unprotected anal sex
* In the past 3 months engaged in sex work for money or drugs
* If a female of childbearing potential (i.e., not post-menopausal or surgically sterile), using an effective method of non-barrier contraception (hormonal contraceptive; intrauterine device (IUD); surgical sterility) from 7 days prior to randomization until the end of the study. All female volunteers must be willing to undergo urine pregnancy tests

Exclusion Criteria

* Confirmed HIV-1 or HIV-2 infection
* Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the investigator would make the volunteer unsuitable for the study, including severe infections requiring treatment such as tuberculosis, and alcohol or drug abuse
* Any of the following abnormal laboratory parameters:

* Haemoglobin \<9.0 g/dL
* Creatinine clearance \<80mL/min, as calculated by Cockcroft-Gault equation
* AST: \>2.5 x ULN
* ALT: \>2.5 x ULN
* Total bilirubin \>1.5 x ULN
* Serum amylase \>1.5 x ULN
* Serum phosphorus \<2.4 mg/dL
* Urinalysis: Two abnormal dipsticks showing any of the following:

* blood = 2+ or more (not due to menses)
* protein = 1+ or more
* leucocytes = 2+ or more
* glucose= 1+ or more
* Confirmed diagnosis of chronic hepatitis B infection (HBsAg positive)
* If female, pregnant or planning a pregnancy within 4 months after enrolment or lactating
* Participation in another clinical study of an investigational product currently, within the 3 months prior to enrolment or expected participation during this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes